

Imaging DIY

Imaging-trained Operator Can Make a Good Clinical Decision

Gary S. Mintz, MD

Cardiovascular Research Foundation

Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

- *Consulting Fees/Honoraria*


Company

- *Boston Scientific, Philips*

Updated meta-analysis of 10 randomized trials (5160 pts) (weighted mean follow up time 13.8 ± 1.4 mos)

IVUS-guided PCI was associated with a lower incidence of

- **Cardiac mortality (0.3% vs 1.1%, OR 0.44, 95% CI 0.26-0.75, $P=0.003$)**
- **MI (0.2% vs 0.9%, OR 0.55, 95% CI 0.32-0.94, $P=0.03$)**
- **TLR (2.4% vs 4.5%, OR 0.57, 95% CI 0.42-0.77, $P<0.001$)**
- **Stent thrombosis (0.3% vs 0.8%, OR 0.44, 95% CI 0.24-0.79, $P=0.006$).**



IVUS use is associated with better outcome



IVUS use is associated with worse outcome

Meta-Analysis of 10 LMCA DES Studies

Meta-Analysis of 7 LMCA DES Studies


All cause mortality

Cardiac mortality



2° Outcome	# Studies	RR	95% CI	P-value
MI	7	0.80	0.61–1.06	0.12
TVR	6	0.89	0.66–1.20	0.44
TLR	3	0.43	0.25–0.73	0.002
ST	4	0.28	0.12–0.67	0.004

MACE




2° Outcome	# Studies	RR	95% CI	P-value
All cause mortality	4	0.55	0.42–0.71	<0.001
Cardiac mortality	5	0.45	0.32–0.62	<0.001
MI	6	0.66	0.55–0.80	<0.001
ST	4	0.48	0.27–0.84	0.001
TLR	6	0.60	0.31–1.18	0.099
TVR	3	0.64	0.26–1.56	0.3


Bayesian network meta-analysis of 31 studies and 17,882 pts comparing clinical outcomes of PCI with BMS and/or DES implantation guided by angiography, IVUS, or OCT

IVUS vs Angiography


■ *Randomized trials (n=17)*
 ■ *Observational, matched studies (n=14)*



OCT vs Angiography




IVUS vs OCT



- Angiography (29 studies; 8434 pts), IVUS (17 studies; 7825 pts), OCT (7 studies; 1623 pts)
- Angiography vs IVUS (24 studies; 14295 pts), Angiography vs OCT (4 studies; 2092 pts), IVUS vs OCT (2 studies; 1045 pts), Angiography vs IVUS vs OCT (1 study; 450 pts)

IVUS Image Interpretation



Stent length determined by landing zones (largest lumen with least plaque burden)



0 —————> 3mm —————> 12mm

Increasingly
aggressive
↓

- 1) Largest reference lumen whether proximal or distal
- 2) Reference midwall
- 3) Reference media-to-media (although this is often “discounted” by approximately 0.5mm)
- 4) Lesion media-to-media (although this is often discounted by 1mm)

OCT Image Interpretation

Can the EEL and Adventitia be visualized?

Yes

- Normal Artery
- Fibrous Plaque

No

Is the signal change in the lumen or the wall?

Lumen

High Attenuation

- Red Thrombus

Low Attenuation

- White Thrombus
- Tissue Protrusion

Wall

High Attenuation



- Lipid

Low Attenuation

- Calcium

Could you draw an outline around the signal change?

How to decide on lesion severity, lesion length, stent sizing, landing zone?




Predictors of DES Early ST, Restenosis, MACE, or DoCE


	IVUS		OCT
	Early ST	Restenosis/MACE	Restenosis/MACE/DoCE
Small MSA or underexpansion in stable lesions Small MLA in ACS/MI lesions	<ul style="list-style-type: none"> • Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8 • Okabe et al. <i>Am J Cardiol</i>. 2007;100:615-20 • Liu et al. <i>JACC Cardiovasc Interv</i>. 2009;2:428-34 • Choi et al. <i>Circ Cardiovasc Interv</i> 2011;4:239-47 	<ul style="list-style-type: none"> • Sonoda et al. <i>J Am Coll Cardiol</i> 2004;43:1959-63 • Hong et al. <i>Eur Heart J</i> 2006;27:1305-10 • Doi et al <i>JACC Cardiovasc Interv</i>. 2009;2:1269-75 • Fujii et al. <i>Circulation</i> 2004;109:1085-1088 • Kang et al. <i>Circ Cardiovasc Interv</i> 2011;4:9-14 • Choi et al. <i>Am J Cardiol</i> 2012;109:455-60 • Song et al. <i>Catheter Cardiovasc Interv</i> 2014;83:873-8 • Kang et al. <i>PLoS One</i> 2015;10(10):e0140421 • Hong et al. <i>JAMA</i> 2015;314(2):155-63. • Lee et al. <i>Rev Esp Cardiol</i> 2017;70:88-95 • Kang et al. <i>PLoS One</i>. 2015 Oct 14;10(10):e0140421 • Katagiri et al. <i>Catheter Cardiovasc Interv</i>. 2019 Jan 31. doi: 10.1002/ccd.28105. 	<ul style="list-style-type: none"> • Prati et al. <i>JACC Cardiovasc Imaging</i> 2015;8:1297-305 • Prati et al. <i>Circ Cardiovasc Interv</i>. 2016;9. pii: e003726. • Soeda et al. <i>Circulation</i> 2015;132:1020-9 • Matsuo et al. <i>Cathet Cardiovasc Interv</i> 2015;87:E9-14 • Prati et al. <i>EuroIntervention</i> 2018, in press
Protrusion in ACS/MI Irregular Protrusion	<ul style="list-style-type: none"> • Choi et al. <i>Circ Cardiovasc Interv</i> 2011;4:239-47 • Hong et al. <i>Int J Cardiol</i> 2013;168:1674-5 		<ul style="list-style-type: none"> • Prati et al. <i>Circ Cardiovasc Interv</i>. 2016;9. pii: e003726. • Soeda et al. <i>Circulation</i> 2015;132:1020-9
Edge problems (geographic miss, secondary lesions, large plaque burden, dissections, etc)	<ul style="list-style-type: none"> • Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8 • Okabe et al., <i>Am J Cardiol</i>. 2007;100:615-20 • Liu et al. <i>JACC Cardiovasc Interv</i>. 2009;2:428-34 • Choi et al. <i>Circ Cardiovasc Interv</i> 2011;4:239-47 	<ul style="list-style-type: none"> • Sakurai et al. <i>Am J Cardiol</i> 2005;96:1251-3 • Liu et al. <i>Am J Cardiol</i> 2009;103:501-6 • Costa et al, <i>Am J Cardiol</i>, 2008;101:1704-11 • Kang et al. <i>Am J Cardiol</i> 2013;111:1408-14 • Kobayashi et al. <i>Circ Cardiovasc Interv</i>. 2016;9:e003553 • Calvert et al. <i>Catheter Cardiovasc Interv</i> 2016;88:340-7 	<ul style="list-style-type: none"> • Prati et al. <i>JACC Cardiovasc Imaging</i> 2015;8:1297-305 • Prati et al. <i>Circ Cardiovasc Interv</i>. 2016;9. pii: e003726. • Ino et al. <i>Circ Cardiovasc Interv</i>. 2016;9:e004231 • Prati et al. <i>EuroIntervention</i> 2018, in press
Stent length (>40mm)		<ul style="list-style-type: none"> • Hong et al. <i>Eur Heart J</i> 2006;27:1305-10 	
Asymmetry/Eccentricity		<ul style="list-style-type: none"> • Suwannasom et al. <i>JACC Cardiovasc Interv</i> 2016;9:1231-42 	

Effect of IVUS-Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: The 1400 patient IVUS-XPL Randomized Clinical Trial

ULTIMATE: Multicenter, Prospective, Randomized Trial Comparing IVUS-guided versus Angiography-guided Implantation of DES in All-comers (n=1448)



No. at risk	0	3	6	9	12
Angiography	700	673	660	643	624
IVUS	700	671	665	654	641




No. at risk	0	3	6	9	12
Angiography	724	706	698	685	676
IVUS	724	715	710	704	696

Hong et al. JAMA 2015;314:2155-63
Zhang et al. J Am Coll Cardiol 2018;72:3126-27

Effect of IVUS Optimization

IVUS-XPL

HR, 0.31 (95% CI, 0.11-0.86)
Log-rank p=0.017




	No. at risk	0	3	6	9	12
No stent optimization	315	299	297	394	285	
Stent optimization	363	362	345	338	334	

*In-stent MLA >distal reference

ULTIMATE

HR: 0.35 (95% CI: 0.135-0.898);
Log rank p=0.029



	No. at risk	0	3	6	9	12
Suboptimal PCI	340	334	329	326	320	
Optimal PCI	384	381	381	378	376	

*In-stent MLA >5.0 mm² or >90% of distal reference lumen
Edge plaque burden <50% with no medial dissection

Hong et al. JAMA 2015;314:2155-63
Zhang et al. J Am Coll Cardiol 2018;72:3126-27

EXCEL Trial

Evaluation of **X**ience versus **C**oronary Artery Bypass Surgery for **E**ffectiveness of **L**eft Main Revascularization

1,905 pts with unprotected LMCAD at 126 sites in 17 countries were prospectively enrolled

R
1:1

CABG (n=957)

PCI with CCr-EES (n=948)


IVUS guided
(n=690)

Angio guided
(n=245)

IVUS Substudy (n=504)

Clinical FU at 30 days, 1 year, 2 years, 3 years

Recommendations for Stent Expansion




Add 0.5 mm² to each location for non-Asian (or larger BSA) pts

Kang et al. *Circulation Cardiovasc Interv.* 2011;4:562-9


Analysis According to MSA Tertiles

IVUS MSA tertiles

	Low	Middle	High
#	172	169	163
MSA mm ² (range)	4.4-8.7	8.8-10.9	11.0-17.8






EXCEL: MSA to Predict LMCA-Related Events



	Adjusted Hazard Ratio (95% CI)	P-value
Final IVUS LM MSA (mm²)	0.84 (0.75-0.94)	0.003
Distal LM lesion location	2.10 (1.0-5.33)	0.05
Diabetes mellitus	1.63 (1.0-2.64)	0.049
ACS presentation	0.60 (0.36-0.99)	0.045









Number at risk:

	0	1	2	3
MSA < 9.8	246	218	199	167
MSA ≥ 9.8	259	242	232	210



Impact of stent oversizing (SO)

Baseline and 6-12 mos QCA and IVUS in 2931 lesions treated with DES (355 SES, 846 PES, 1387 ZES, and 343 EES)



Underexpansion is often lumped with malapposition - even by people who should know better. “Underdeployment” can mean anything.

Stent Thrombosis – No single set of predictors

	JEREMIAS (registry)	IAKO'VOU (registry)	MORENO (RCT's)	e-CYPHER (registry)	ARRIVE 1 (registry)	Cheneau et al. (registry)
Advanced age				Yes		
Plx Non-compliance	Yes	Yes				
Diabetes		Yes		Yes	Yes	
ACS/AMI				Yes		
Renal failure		Yes				
Low LVEF		Yes				
Bifurcation		Yes				
Calcifications				Yes		
Total occlusion				Yes		
MVD				Yes		
Total stent length			Yes			
Malapposition						Yes
Number of stents			Yes			

AMI = acute myocardial infarction; LVEF = left ventricular ejection fraction; RCT = randomized clinical trial;
MVD = multivessel disease.
Modified from Urban. *EuroPCR*, 2006. Oral presentation; Cheneau et al. *Circulation*, 2003; 108:43.

41

Summary

- **Stent thrombosis is multifactorial**
 - Anatomic, clinical, pharmacologic
- **Early stent thrombosis (~ 0.6%) is related to:**
 - Lesion complexity
 - Stent malapposition
 - Variable anti-platelet agent responsiveness
 - Early discontinuation of anti-platelet therapy (strongest risk factor)
- **LST and VLST are rare but serious complications of DES**
 - It was not seen in patients who remain on dual anti-platelet therapy in the RESEARCH/TSEARCH analysis by Ong et al, or the TAXUS meta-analysis (1 patient only)
- **Current ESC PCI guidelines now recommend 6-12 months of dual anti-platelet therapy after DES**
 - The TAXUS® Express²™ DFU recommends 6 months of dual anti-platelet therapy

48

Events related to acute stent malapposition

	Study		Follow-up	Acute malapposition	No acute malapposition
Steinberg et al. JACC Cardiovasc Interv 2010;3:486-94	Combined TAXUS	IVUS	9 mos	8.2% MACE	10.7% MACE
Van der Hoeven et al. JACC Cardiovasc Interv 2008;1:192-201	MISSION-AMI	IVUS	9 mos	0% ST	0% ST
Guo et al. Circulation 2010;122:10-77-84	HORIZONS-AMI	IVUS	13 mos	0% ST	0% ST
Soeda et al. Circulation 2015;132:1020-9		OCT	1 yr	4.4% DoCE	4.8% DoCE
Prati et al. JACC Cardiovasc Imaging 2015;8:1297-305	CLI-OPCI-II	OCT	1 yr	13% MACE	10% MACE
Wang et al. J Am Heart Assoc. 2016;5. pii: e004438. doi: 10.1161	ADAPT-DES	IVUS	2 yrs	5.2% MACE (0.65% ST)	4.5% MACE (0.43% ST)
Prati et al. Circ Cardiovasc Interv. 2016;9. pii: e003726.	CLI-OPCI-ACS	OCT	9 mos	12.8% MACE	12.4% MACE

CLI-OPCI: In 864 pts undergoing PCI, post-procedural OCT revealed a variable grade of acute stent malapposition in 72.3% without correlation between maximal strut-vessel distance vs longitudinal extension.

Acute Malapposition >0.2 mm thickness and >2.2mm length			
	Yes (371/1020)	No (649/1020)	P-value
MACE at 302 (IQR 127-567) days	11.0%	13.0%	0.4
Death	3.1%	2.7%	0.8
Myocardial infarction	5.3%	8.6%	0.08
Periprocedure	1.9%	2.9%	0.4
Follow-up	3.5%	5.7%	0.19
TLR	5.7%	6.8%	0.4
Stent thrombosis	2.4%	3.7%	0.6
Increasing severity of malapposition length and distance			
Malapposition distance <0.2mm	227/1020 (22.3%)	HR: 0.97	1.0
Malapposition distance 0.2-0.4mm	324/1020 (31.8%)	HR: 0.88	0.5
Malapposition distance >0.4mm	186/1020 (18.2%)	HR: 1.24	0.3
Malapposition length <2mm	224/1020 (22.4%)	HR: 1.19	0.4
Malapposition length 2-4mm	184/1020 (18.0%)	HR: 1.17	0.5
Malapposition length 4-6mm	123/1020 (12.1%)	HR: 0.81	0.5
Malapposition length 6-8mm	89/1020 (8.7%)	HR: 0.69	0.3
Malapposition length 8-10mm	50/1020 (4.9%)	HR: 0.71	0.5
Malapposition length >10mm	67/1020 (6.6%)	HR: 1.03	0.9

Poll on ACC.ORG (April 9, 2019)

AMERICAN COLLEGE of CARDIOLOGY

Guidelines | JACC | ACC19 | Membership | About ACC

All Types Search

Dr. Gary S. Mintz, MD, FACC | Logout

Clinical Topics Latest In Cardiology Education and Meetings Tools and Practice Support My ACC

Poll: Use of IVUS for Guidance in Coronary Stent Implantation

Apr 09, 2019 | Jad Omran, MD

Share via: Facebook, Twitter, LinkedIn, Email, Print, Save to Library

Font Size A A A

The recently published ULTIMATE (A Multicenter, Prospective, Randomized Trial Comparing Intravascular Ultrasound-Guided Versus Angiography-Guided Implantation of Drug-Eluting Stent in All-Comers)¹ is a multicenter randomized trial that showed lower target lesion failure (composite endpoint of cardiac death, target vessel myocardial infarction, and clinically driven target vessel revascularization) in an intravascular ultrasound (IVUS) group compared with angiography only in patients undergoing second-generation drug-eluting stent implantation.

Based on the results of ULTIMATE, has your use of IVUS for guidance in coronary stent implantation changed?

- I now perform IVUS routinely during coronary interventions.
- I have increased my use of IVUS during coronary interventions.
- My use of IVUS during coronary interventions is unchanged and used in less than 10% of cases.
- IVUS is not available in my laboratory.

View Results [Vote](#)

Recommended Content for You

Recent items based on your interests:

- Outcomes of Transcatheter Repair for Tricuspid Regurgitation
Apr 16, 2019
- Catheter Ablation for VF Storm After MI
Apr 16, 2019
- PCI in Older Adults With STEMI and Cardiogenic Shock
Apr 16, 2019
- Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease
Apr 23, 2019

Important updates from the American Diabetes Association® about CV risk reduction

[LEARN MORE >](#)

AMR19-0015I 6/19

References

- Zhang J, Gao X, Kan J, et al. Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial. *J Am Coll Cardiol* 2018;72:3126-37.

Share via: Facebook, Twitter, LinkedIn, Email, Print, Save to Library

Clinical Topics: Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Interventions and Imaging, Angiography, Nuclear Imaging

Keywords: Drug-Eluting Stents, Prospective Studies, Myocardial Infarction, Stents, Angiography, Coronary Angiography

Based on the results of ULTIMATE, has your use of IVUS for guidance in coronary stent implantation changed?

I now perform IVUS routinely during coronary interventions. (6 votes) 16.67%

I have increased my use of IVUS during coronary interventions. 36.11% (13 votes)

My use of IVUS during coronary interventions is unchanged and used in less than 10% of cases. (16 votes) 44.44%

IVUS is not available in my laboratory. (1 votes) 2.78%

Total Votes: 36

[Like 0](#) [Share](#)

[Tweet](#)

[Return To Poll](#)

Fellows and recent graduates, do you receive training in...

tctMD
By the Cardiovascular Research Foundation

News Conferences Slides & More Topics **FELLOWS FORUM**

Training in Intracoronary Imaging and Physiology

In what country do you reside? *

Do you receive training in (or exposure to) intravascular ultrasound (IVUS)? *

- No
- Yes, but rudimentary
- Yes, sufficient to perform the procedure, interpret images, make measurements and use the information clinically
- Yes, expert level

Do you receive training in (or exposure to) Intracoronary Physiology (FFR)? *

- No
- Yes, but rudimentary
- Yes, sufficient to perform the procedure, interpret images, make measurements and use the information clinically
- Yes, expert level

Do you receive training in (or exposure to) Optical Coherence Tomography (OCT)? *

- No
- Yes, but rudimentary
- Yes, sufficient to perform the procedure, interpret images, make measurements and use the information clinically
- Yes, expert level

	No	Rudimentary	Sufficient*	Expert
FFR	12%	24%	42%	22%
IVUS	15%	37%	31%	18%
OCT	38%	28%	23%	10%

**perform the procedure, interpret images, make measurements, and use information clinically*

Cath-lab based imaging program

- Director
- Dedicated Technicians, Nurses, and/or Fellows
- Procedure standards
- Image acquisition protocol(s)
- Reports
- Housekeeping issues
- Visit a busy lab to see how it integrates imaging into clinical practice
- Show cases in weekly cath conference

